ALNY
Alnylam Pharmaceuticals Inc
223.90$
+1.8%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 11.2% | 19.5% | 13.3% | 10.4% | 17.1% | 17.3% | 12.0% | 18.5% | 15.8% | 24.4% | 18.1% | 23.1% | 20.3% | |
| 88.8% | 80.5% | 86.7% | 89.6% | 82.9% | 82.7% | 88.0% | 81.5% | 84.2% | 75.6% | 81.9% | 76.9% | 79.7% | |
| 33.7% | 61.9% | 52.8% | 44.6% | 54.1% | 50.6% | 44.6% | 41.8% | 28.7% | 33.9% | 31.3% | 32.0% | 31.4% | |
| 26.5% | 45.1% | 42.6% | 37.6% | 44.1% | 49.8% | 40.4% | 41.8% | 25.8% | 29.7% | 27.6% | 27.0% | 27.4% | |
| 60.3% | 106.9% | 95.4% | 82.2% | 98.2% | 100.4% | 85.0% | 83.6% | 54.7% | 63.6% | 58.9% | 59.0% | 58.9% | |
| 28.5% | -26.5% | -8.8% | 7.4% | -15.4% | -17.7% | 3.0% | -2.1% | 29.5% | 12.0% | 23.0% | 17.9% | 20.8% | |
| 4.1% | 7.1% | 7.1% | 5.0% | 6.9% | 6.6% | 6.5% | 5.2% | 3.6% | 11.8% | 5.9% | 6.4% | 6.8% | |
| 20.1% | -31.3% | -12.9% | -1.7% | -21.7% | -32.7% | -7.0% | -4.6% | 19.1% | 14.7% | 19.0% | 13.8% | 16.6% | |
| 0.4% | 0.0% | 0.5% | 0.9% | 0.6% | -18.6% | 2.7% | 4.0% | -1.0% | -2.3% | -1.3% | 1.0% | -0.8% | |
| 19.7% | -31.4% | -13.3% | -2.6% | -22.3% | -14.1% | -9.7% | -8.6% | 20.1% | 17.0% | 17.6% | 12.7% | 16.8% | |
| 26.0% | -21.1% | -3.0% | 5.6% | -12.0% | -23.8% | 1.9% | 2.4% | 23.8% | 27.7% | 26.1% | 19.0% | 23.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.